Dr. Jennifer Yarden is the cofounder of Curewize Health Ltd. Dr. Yarden was formerly the Director of Clinical Development at Glycominds with expertise in the design, development and commercialization of in vitro diagnostic assays and kits. Dr. Yarden strategically planned & managed international clinical trials and contributed to reimbursement strategy and marketing of laboratory assays. Prior to Glycominds Jennifer was Senior CRA (Clinical Research Associate) and Scientific Writer at Deep Breeze Ltd., a company dealing in the diagnosis and prognosis of lung diseases. Dr. Yarden holds a PhD in Medical Science from KU Leuven, Belgium with a focus on disease biomarkers and a B.Sc. in Biotechnology with honors from Tel Chai Academic College, Israel. Dr. Yarden was also apointed as the CEO of BioShai dealing with biomakers for Parkinson's disease.DR. NIR DOTAN PHD,
Dr. Nir Dotan was the cofounder, Vice President and CTO of Glycominds Ltd. and has over 15 years of experience in the development and commercialization of in vitro diagnostic assays and kits. Dr. Dotan successfully invented, validated and translated to clinical practice the IBDX blood test as an aid in diagnosis and risk stratification of Crohn's disease patients. Dr. Dotan's proven experience in clinical and technological development and commercialization of biomarkers from bench to the market is a great asset to Curewize. Dr. Dotan has a PhD in Biotechnology from the Tel Aviv University and was also appointed the CTO of BioShai.Dr. Keren Shichrur,
Dr. Keren Shichrur received her MSc from the Tel Aviv University, Department of Human Microbiology. Following the completion of her MSc studies, she worked as a research assistant in XTL-Biopharmaceuticals Company in Rehovot developing a HCV Cell-based assay. She has received her PhD from the Tel Aviv University, Department of Molecular Biology of Plants. Dr. Shichrur was assigned to find new targets in diagnosis and therapy of childhood malignancies in the Molecular Oncology Laboratory for the Pediatric Hematology Oncology Department at the Schneider Children's Medical Center of Israel during her post-doc studies. During this period Dr. Shichrur started the development of the ProALL assay.
Prof. Isaac Yaniv is the Director of the Division of Pediatric Hematology Oncology at Schneider’s Children’s Medical Center of Israel. Prof. Yaniv graduated the Sackler Faculty of Medicine in 1977. He is board certified in Pediatrics, Hematology and Pediatric Hematology Oncology, and a Professor of Pediatrics at the Faculty. Prof. Yaniv is currently the chairman of the Israeli Society of Pediatric Hematology Oncology. Following training in France and the U.S. Prof. Yaniv established in 1992 the first pediatric stem cell transplantation unit in Israel. In 2001 Prof. Yaniv was nominated chairman of Pediatric Hematology Oncology at the Schneider Children's Medical Center of Israel. Prof. Yaniv is a member of the executive committee of the SIOPEN group as well as of the pediatric board of the EBMT. He is a member of the national ethics committee and a consultant for the Israeli Ministry of Health. Prof. Yaniv's research interests include cancer prognostics, pediatric stem cell transplantation, molecular genetics of childhood cancer, with special interest in childhood leukemia and Ewing's sarcoma.DR. SMADAR AVIGAD,
Dr. Smadar Avigad is the Head of Molecular-Oncology Lab at Felsenstein Medical Research Center, Israel. Dr. Avigad has received her PhD from the Tel Aviv University, Department of Human Genetics. Following the completion of her studies, she was appointed to establish and lead the Molecular Oncology Laboratory for the Pediatric Hematology Oncology Department at the Schneider Children's Medical Center of Israel. The lab is the major Israeli center for diagnostic and analysis of pediatric cancers. Dr. Avigad head the molecular oncology lab during the last 20 years. She is an expert in molecular biology of childhood malignancies, with publications in over 60 articles in peer-reviewed journals. Dr. Avigad’s main focus is translational medicine, with an aim of integrating the data obtained in the lab back to the clinic. The molecular oncology lab is the National lab for the detection of response to treatment of all the pediatric leukemia patients in Israel, which enables a more individualized therapy.Mr. OSSIE WEITZMAN,
Mr. Ossie Weitzman is the co-founder of Curewize. He is a UK qualified Chartered Accountant with over 30 years financial management and business development experience. Mr. Weitzman has worked with a large number of technology companies in the life science and other fields, both in Israel and the UK, assisting them in defining and executing business strategies. Mr. Weitzman assists clients, both in Israel and internationally, with business plan strategies, which maximize the chances of achieving success in business and raising investment. He has used this experience to good effect in helping to develop Curewize's sound business strategy.